Author

A. Dolnikova

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

P. Klener· 2 shared A. Berkova· 1 shared A. Rajmonova· 1 shared D. Sovilj· 1 shared E. Reznickova· 1 shared J. Senavova· 1 shared K. Kozlanska· 1 shared K. Kupcova· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

P. Klener

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies

N. Bettazova, J. Senavova, K. Kupcova, D. Sovilj, A. Rajmonova, L. Andera, K. Svobodova, A. Berkova, V. Herman, Z. Zemanova, L. Daumova, A. Dolnikova, R. E. Davis, M. Trneny, P. Klener, O. Havranek

This study investigates how PIK3CA gain and PTEN loss affect MCL biology and drug response, finding reduced BCR dependence and increased therapy resistance.

bioRxiv · Apr 30, 2024Cancer Biology

Synthesis and structural optimization of 2,7,9-trisubstituted purin-8-ones as FLT3-ITD inhibitors

M. Tomanova, K. Kozlanska, R. Jorda, L. Jedinak, T. Havlikova, E. Reznickova, M. Perina, P. Klener, A. Dolnikova, P. Cankar, V. Krystof

The paper designs and evaluates 2,7,9-trisubstituted purin-8-ones as FLT3-ITD inhibitors, identifying compound 15a with improved selectivity and activity in vitro and in vivo.

bioRxiv · Dec 10, 2022Pharmacology & Toxicology